BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2476601
,
KLK3
,
Fatty acid metabolic process
,
Influenza
,
Retina
,
DNA fingerprint
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PAZ domain superfamily
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Saphenous vein
Oral mucosa
Leukocyte (polymorphonuclear) of peripheral blood
Vena cava
Salivary gland
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Pyloric ulcer
Multiple-resistant Staphylococcus aureus infection
Helicobacter pylori gastrointestinal tract infection
Shock
Disease due to Orthopoxvirus
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Gold
Diphenylamine
PF 00299804
KIN001-242
beta-1,3-glucan
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Ar
MOV10L1
TSTA3
TSC1
C15orf65
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
C. elegans infection resistant and sensitive strains infected with Orsay virus for 4d
Duodenal ulcer disease caused by Helicobacter pylori - miRNA expression profile
L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
GLD-2 and RNP-8 associated transcripts in Caenorhabditis elegans
Hematopoeitic stem and progenitor cells: specific TORC1 knockout
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for PAZ domain superfamily
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ